Algorae Pharmaceuticals Ltd (asx:1AI) Share Price

Company Profile

Business description
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for under met medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. The products of the company comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The company is conceptualized to be a potential treatment for dementia, including Alzheimer’s disease, NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.
Contact
525 Collins Street
Level 23, Rialto South Tower
MelbourneVIC3000
AUS
T: +61 422180317
https://www.algoraepharma.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
48

Recommended

Earnings growth fails to excite investors worried about AI disruption.

Nathan Zaia | 25 February 2026

Impressive cost control and record production leads to higher dividend.

Mark Taylor | 25 February 2026

The market responded favourably to results but shares still underpriced.

Johannes Faul, CFA | 24 February 2026

Index	Last price	Change	% Change
All Ordinaries	9,359.00	50.70	0.54%
CAC 40	8,533.67	14.46	0.17%
DAX 40	25,133.06	146.81	0.59%
Dow JONES (US)	49,257.64	83.14	0.17%
FTSE 100	10,764.36	83.77	0.78%
HKSE	26,765.72	175.40	0.66%
NASDAQ	23,092.93	229.25	1.00%
Nikkei 225	58,583.12	1,262.03	2.20%
NZX 50 Index	13,525.58	6.73	-0.05%
S&P 500	6,924.43	34.36	0.50%
S&P/ASX 200	9,128.30	44.20	0.49%
SSE Composite Index	4,147.23	29.82	0.72%